
# Title 42— THE PUBLIC HEALTH AND WELFARE
### CHAPTER 6A— PUBLIC HEALTH SERVICE
#### § 262. Regulation of biological products
##### (a) Biologics license
######## (D) Postmarket studies and clinical trials; labeling; risk evaluation and mitigation strategy .

A person that submits an application for a license under this paragraph is subject to sections 505( o ), 505(p), and 505–1 of the Federal Food, Drug, and Cosmetic Act [ 21 U.S.C. 355 ( o ), (p), 355–1].

(E)

(i) The Secretary may rely upon qualified data summaries to support the approval of a supplemental application, with respect to a qualified indication for a drug, submitted under this subsection, if such supplemental application complies with the requirements of subparagraph (B) of section 505(c)(5) of the Federal Food, Drug, and Cosmetic Act [ 21 U.S.C. 355(c)(5) ].

(ii) In this subparagraph, the terms “qualified indication” and “qualified data summary” have the meanings given such terms in section 505(c)(5) of the Federal Food, Drug, and Cosmetic Act.

(3) The Secretary shall prescribe requirements under which a biological product undergoing investigation shall be exempt from the requirements of paragraph (1).
